TY - JOUR
T1 - Fetal hypoplastic lungs have multilineage inflammation that is reversed by amniotic fluid stem cell extracellular vesicle treatment
AU - Antounians, Lina
AU - Figueira, Rebeca Lopes
AU - Kukreja, Bharti
AU - Litvack, Michael L.
AU - Zani-Ruttenstock, Elke
AU - Khalaj, Kasra
AU - Montalva, Louise
AU - Doktor, Fabian
AU - Obed, Mikal
AU - Blundell, Matisse
AU - Wu, Taiyi
AU - Chan, Cadia
AU - Wagner, Richard
AU - Lacher, Martin
AU - Wilson, Michael D.
AU - Post, Martin
AU - Kalish, Brian T.
AU - Zani, Augusto
N1 - Publisher Copyright:
Copyright © 2024 The Authors, some rights reserved;
PY - 2024/7/26
Y1 - 2024/7/26
N2 - Antenatal administration of extracellular vesicles from amniotic fluid stem cells (AFSC-EVs) reverses features of pulmonary hypoplasia in models of congenital diaphragmatic hernia (CDH). However, it remains unknown which lung cellular compartments and biological pathways are affected by AFSC-EV therapy. Herein, we conducted single-nucleus RNA sequencing (snRNA-seq) on rat fetal CDH lungs treated with vehicle or AFSC-EVs. We identified that intra-amniotically injected AFSC-EVs reach the fetal lung in rats with CDH, where they promote lung branching morphogenesis and epithelial cell differentiation. Moreover, snRNA-seq revealed that rat fetal CDH lungs have a multilineage inflammatory signature with macrophage enrichment, which is reversed by AFSC-EV treatment. Macrophage enrichment in CDH fetal rat lungs was confirmed by immunofluorescence, flow cytometry, and inhibition studies with GW2580. Moreover, we validated macrophage enrichment in human fetal CDH lung autopsy samples. Together, this study advances knowledge on the pathogenesis of pulmonary hypoplasia and further evidence on the value of an EV-based therapy for CDH fetuses.
AB - Antenatal administration of extracellular vesicles from amniotic fluid stem cells (AFSC-EVs) reverses features of pulmonary hypoplasia in models of congenital diaphragmatic hernia (CDH). However, it remains unknown which lung cellular compartments and biological pathways are affected by AFSC-EV therapy. Herein, we conducted single-nucleus RNA sequencing (snRNA-seq) on rat fetal CDH lungs treated with vehicle or AFSC-EVs. We identified that intra-amniotically injected AFSC-EVs reach the fetal lung in rats with CDH, where they promote lung branching morphogenesis and epithelial cell differentiation. Moreover, snRNA-seq revealed that rat fetal CDH lungs have a multilineage inflammatory signature with macrophage enrichment, which is reversed by AFSC-EV treatment. Macrophage enrichment in CDH fetal rat lungs was confirmed by immunofluorescence, flow cytometry, and inhibition studies with GW2580. Moreover, we validated macrophage enrichment in human fetal CDH lung autopsy samples. Together, this study advances knowledge on the pathogenesis of pulmonary hypoplasia and further evidence on the value of an EV-based therapy for CDH fetuses.
UR - http://www.scopus.com/inward/record.url?scp=85199935743&partnerID=8YFLogxK
U2 - 10.1126/sciadv.adn5405
DO - 10.1126/sciadv.adn5405
M3 - Article
C2 - 39058789
AN - SCOPUS:85199935743
SN - 2375-2548
VL - 10
JO - Science Advances
JF - Science Advances
IS - 30
M1 - eadn5405
ER -